UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now.
Posts Tagged ‘NASDAQ:REGN’
10 Best Non-Mega Cap NASDAQ Stocks to Buy Right Now
In today’s evolving market, investor attention is beginning to shift away from the dominant “Magnificent Seven” mega-cap stocks and toward lesser-known opportunities on ...
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now.
11 Best Debt-Free Stocks to Invest in Right Now
It is widely understood that employing debt to fund operations can act as a powerful financial tool. But debt doesn't come without its trade-offs.
Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts.
13 Most Undervalued Large Cap Stocks to Buy According to Analysts
On July 3, Ben Preston, Portfolio Manager at Orbis Investments, appeared on CNBC to suggest that investors look past the constant political headlines and market volatility and...
Regeneron Pharmaceuticals (REGN) Announces Approval of Dupixent in the US
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.
11 Best 52-Week Low Stocks to Buy Right Now
On July 2, Tom Lee, Fundstrat's Head of Research and CIO, joined CNBC Television to discuss market conditions.
Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.
10 Best Value Stocks to Buy According to Billionaires
The H1 2025 has been a roller coaster ride for the investors.
Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential.
12 Best S&P 500 Stocks With Huge Upside Potential
Bankim Chadha, Deutsche Bank's chief global strategist, joined CNBC's 'The Exchange' on June 24 to express a cautionary view regarding further monetary policy movement despite...
UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold
On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price target at $580.
7 52-Week Low Dividend Stocks to Consider
Since 2023, dividend stocks have faced challenges and have yet to regain momentum.
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now.
11 Most Profitable NASDAQ Stocks to Buy Now
Earlier on May 30, Siebert Financial CIO Mark Malek appeared on CNBC to discuss the tariff headwinds swirling around the markets and which sectors could then rise above the noise...
8 Best Inexpensive Stocks to Buy Right Now
On June 7, Torsten Slok, Apollo Global Management, joined 'Closing Bell Overtime' on CNBC to discuss the US jobs report and the broader economic landscape.
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack.
Morgan Stanley Trims Regeneron (REGN) Price Target, Maintains Overweight Rating
Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock.
Regeneron Pharmaceuticals, Inc. (REGN)’s Weight-Loss Drug Aids Muscle Preservation in Wegovy Users
Regeneron Pharmaceuticals, Inc.
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply
On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc.
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week
We recently published a list of These 10 Stocks Just Rocked The Market.
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results
Regeneron Pharmaceuticals, Inc.
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed On Friday
We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.
RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results
Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29.
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the innovative Gibson SOLA system into its laboratories.
Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer commented on the recent downgrade of US credit.
Regeneron Pharmaceuticals to Acquire 23andMe for $256M
23andMe had filed for bankruptcy protection in March this year, while REGN was the sole bidder for its assets.
10 Worst Blue Chip Stocks to Buy
As per Niamh Brodie-Machura, Co-Chief Investment Officer at Fidelity International, the effect of tariffs is expected to shift lower as and when the deals are made, supply chains...
10 Jim Cramer Stocks with Huge Upside Potential
“I want to pull back the curtain and show you how a professional looks for stocks to buy and knows what to sell. There's no magic. There's no hidden talent.
11 Cheap ESG Stocks to Buy According to Hedge Funds
These days, it seems like everyone wants to wear the “saving the world” cape.
Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential
Mario Gabelli needs no introduction, having risen to become one of the most successful money managers on Wall Street, backed by a research-driven equity investment style.
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years
“This week we're celebrating the show's 20th anniversary, a little over a month late, but better late than never.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025Regeneron Pharmaceuticals, Inc. misses on earnings expectations.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
11 Blue Chip Stocks to Invest in at 52-Week Lows
For the first time since 2023, the S&P 500 was seen in the market correction territory, according to US Bank (Wealth Management).
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
11 Best Extremely Profitable Stocks to Buy According to Analysts
We recently covered 10 Best Stocks to Buy Now For the Long Term, where we talked about the market outlook amidst the tariff situation and uncertainty.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Jim Cramer’s Latest Stock Moves: Top 10 Calls
Jim Cramer in a recent program on CNBC expressed his frustration over the recent market selloff following tariff uncertainties.
What Did Jim Cramer Say About These 19 Stocks Recently?
Jim Cramer kicked off his latest episode of Mad Money by highlighting the wild swings in the market, the ongoing trade war with Canada, and the growing concerns about tariffs ...
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
11 Oversold Blue Chip Stocks to Buy According to Hedge Funds
The uncertainty related to the tariff announcements continues to influence Wall Street.
10 Worst Performing Large Cap Stocks to Buy According to Analysts
On January 21, Russell Investment released its Equity Factor report highlighting key trends and performances in global equity markets during the fourth quarter of 2024.
15 Stocks That Will Go to The Moon According to Analysts
While stocks initially fell based on worries regarding Trump tariffs on America’s major trading partners, major indexes recovered from their initial losses as the President ...
12 Best Growth Stocks to Invest In According to Analysts
Companies experiencing above-average earnings growth, which is often fueled by innovations and market expansions, are known as growth stocks.
